[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA200870411A1 - Полипептиды с усиленным противовоспалительным и пониженным цитотоксическим свойствами и связанные с ними способы - Google Patents

Полипептиды с усиленным противовоспалительным и пониженным цитотоксическим свойствами и связанные с ними способы

Info

Publication number
EA200870411A1
EA200870411A1 EA200870411A EA200870411A EA200870411A1 EA 200870411 A1 EA200870411 A1 EA 200870411A1 EA 200870411 A EA200870411 A EA 200870411A EA 200870411 A EA200870411 A EA 200870411A EA 200870411 A1 EA200870411 A1 EA 200870411A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inflammatory
polypeptides
related methods
enhanced anti
cytotoxic properties
Prior art date
Application number
EA200870411A
Other languages
English (en)
Other versions
EA022780B1 (ru
Inventor
Джеффри В. Равеч
Канеко Йосикатус
Фальк Ниммерьян
Original Assignee
Дзе Рокфеллер Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38581601&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200870411(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Дзе Рокфеллер Юниверсити filed Critical Дзе Рокфеллер Юниверсити
Publication of EA200870411A1 publication Critical patent/EA200870411A1/ru
Publication of EA022780B1 publication Critical patent/EA022780B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Изобретение связано с полипептидом, содержащим по меньшей мере одну FC-область IgG, где указанный полипептид имеет более высокую противовоспалительную активность и более низкую цитотоксическую активность по сравнению с неочищенным антителом, и способы получения такого полипептида.
EA200870411A 2006-04-05 2007-04-03 СПОСОБ ПОВЫШЕНИЯ ПРОТИВОВОСПАЛИТЕЛЬНОЙ АКТИВНОСТИ И СНИЖЕНИЯ ЦИТОТОКСИЧЕСКОЙ АКТИВНОСТИ ПРЕПАРАТА IgG EA022780B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78938406P 2006-04-05 2006-04-05
PCT/US2007/008396 WO2007117505A2 (en) 2006-04-05 2007-04-03 Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods

Publications (2)

Publication Number Publication Date
EA200870411A1 true EA200870411A1 (ru) 2009-04-28
EA022780B1 EA022780B1 (ru) 2016-03-31

Family

ID=38581601

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200870411A EA022780B1 (ru) 2006-04-05 2007-04-03 СПОСОБ ПОВЫШЕНИЯ ПРОТИВОВОСПАЛИТЕЛЬНОЙ АКТИВНОСТИ И СНИЖЕНИЯ ЦИТОТОКСИЧЕСКОЙ АКТИВНОСТИ ПРЕПАРАТА IgG

Country Status (13)

Country Link
US (14) US10167332B2 (ru)
EP (3) EP3456351A1 (ru)
JP (6) JP6084761B2 (ru)
CN (1) CN101432301B (ru)
AU (1) AU2007235413B2 (ru)
CA (1) CA2647524C (ru)
EA (1) EA022780B1 (ru)
HK (1) HK1124074A1 (ru)
IL (1) IL194526A (ru)
MX (1) MX2008012843A (ru)
NZ (1) NZ572379A (ru)
WO (1) WO2007117505A2 (ru)
ZA (1) ZA200808900B (ru)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470318B2 (en) 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US10167332B2 (en) 2006-04-05 2019-01-01 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US10844125B2 (en) 2015-03-04 2020-11-24 The Rockefeller University Anti-inflammatory polypeptides
US10894832B2 (en) 2011-12-19 2021-01-19 The Rockefeller University Anti-inflammatory polypeptides

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080206246A1 (en) * 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
AU2008282218A1 (en) 2007-07-31 2009-02-05 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
ES2613963T3 (es) 2008-01-18 2017-05-29 Medimmune, Llc Anticuerpos manipulados con cisteína para conjugación específica de sitio
WO2009132130A2 (en) 2008-04-22 2009-10-29 The Rockefeller University Methods of identifying anti-inflammatory compounds
EP2233499A1 (en) 2009-03-26 2010-09-29 CSL Behring AG Antibody composition with altered Fab sialylation
EP2233502A1 (en) 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
EP2711018A1 (en) 2009-06-22 2014-03-26 MedImmune, LLC Engineered Fc regions for site-specific conjugation
WO2011138354A1 (en) 2010-05-07 2011-11-10 Csl Behring Ag Antibody composition obtained by fractionation of plasma immunoglobulins affinity chromatography on a sambucus nigra affinity column
MX339809B (es) * 2010-05-27 2016-06-09 Merck Sharp & Dohme Corp * Metodo para preparar anticuerpos con propiedades mejoradas.
AR085302A1 (es) 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EP3539982B1 (en) 2011-12-23 2025-02-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014149067A1 (en) 2013-03-15 2014-09-25 Momenta Pharmaceuticals, Inc. Methods related to ctla4-fc fusion proteins
EA038968B1 (ru) 2013-04-18 2021-11-16 Институт Насьональ Де Ла Сант Эт Де Ла Решерш Медикаль Композиция с пониженной иммуногенностью
WO2014179601A2 (en) * 2013-05-02 2014-11-06 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
ES2708759T3 (es) 2013-05-13 2019-04-11 Momenta Pharmaceuticals Inc Procedimientos para el tratamiento de la neurodegeneración
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
WO2015057622A1 (en) 2013-10-16 2015-04-23 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
AR100716A1 (es) * 2014-06-02 2016-10-26 Laboratoire Français Du Fractionnement Et Des Biotechnologies Producción de fragmentos fc
AU2015332634B2 (en) 2014-10-15 2020-05-14 Xenothera Composition with reduced immunogenicity
WO2018026600A1 (en) 2016-08-03 2018-02-08 The Board Of Trustees Of The Leland Stanford Junior University Disrupting fc receptor engagement on macrophages enhances efficacy of anti-sirpalpha antibody therapy
US11505606B2 (en) 2016-09-14 2022-11-22 Teneobio, Inc. CD3 binding antibodies
AU2018308364C1 (en) 2017-07-26 2023-02-16 Forty Seven, LLC Anti-SIRP-alpha antibodies and related methods
CN111133007A (zh) 2017-09-13 2020-05-08 特尼奥生物股份有限公司 与胞外酶结合的重链抗体
EA202091521A1 (ru) 2017-12-19 2020-10-22 Дзе Рокфеллер Юниверсити ВАРИАНТЫ ДОМЕНА Fc IgG ЧЕЛОВЕКА С УЛУЧШЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
KR20200104364A (ko) 2017-12-27 2020-09-03 테네오바이오, 인코포레이티드 Cd3-델타/엡실론 이형이량체 특이적 항체
CN118063599A (zh) 2018-07-03 2024-05-24 吉利德科学公司 靶向hiv gp120的抗体和使用方法
MA53493A (fr) 2018-08-31 2021-07-07 Alx Oncology Inc Polypeptides leurres
SG11202102713TA (en) 2018-09-21 2021-04-29 Teneobio Inc Methods for purifying heterodimeric, multispecific antibodies
JP2022502466A (ja) * 2018-10-11 2022-01-11 モメンタ ファーマシューティカルズ インコーポレイテッド 高度にシリル化されたＩｇＧ組成物による処理
MX2021004732A (es) 2018-10-26 2021-06-04 Teneobio Inc Anticuerpos de cadena pesada que se unen a cd38.
CN110297093B (zh) * 2019-03-18 2022-04-22 山西瑞豪生物科技有限公司 一种检测人免疫球蛋白g4的方法和试剂盒
KR102549282B1 (ko) * 2019-11-18 2023-06-30 건국대학교 산학협력단 시알산화된 면역글로불린을 유효성분으로 포함하는 염증성 질환의 치료용 조성물
AU2020405183A1 (en) 2019-12-18 2022-06-09 TeneoFour, Inc. Heavy chain antibodies binding to CD38
WO2022271987A1 (en) 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same
WO2024136368A1 (ko) * 2022-12-21 2024-06-27 건국대학교 산학협력단 α-2,6-시알산화 면역글로불린의 안구 건조증 또는 염증성 안과 질환의 예방 또는 치료 용도

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
FR2556219B1 (fr) * 1983-12-07 1987-06-26 Merieux Inst Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5047335A (en) * 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
HUT64476A (en) * 1990-11-23 1994-01-28 Gen Hospital Corp Process for inhibiting interacton between proteins and carbohydrate causing cell-adhesion
US5453272A (en) 1992-10-02 1995-09-26 Alberta Research Council Lectin derived carbohydrate binding-peptide
US5707622A (en) * 1994-03-03 1998-01-13 Genentech, Inc. Methods for treating ulcerative colitis
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US20020045207A1 (en) 1997-10-31 2002-04-18 Lynne A. Krummen Glycoprotein production process
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
ES2237420T5 (es) * 1999-04-15 2010-03-03 Crucell Holland B.V. Produccion de proteina recombinante en una celula humana.
DE19927835A1 (de) * 1999-06-18 2000-12-21 Clariant Gmbh Verwendung von verbesserten Cyanpigmenten in elektrophotographischen Tonern und Entwicklern, Pulverlacken und Ink-Jet-Tinten
EP1333032A4 (en) * 2000-10-06 2005-03-16 Kyowa Hakko Kogyo Kk METHOD FOR PURIFYING ANTIBODIES
US7064191B2 (en) * 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
AU2002220404A1 (en) 2000-11-20 2002-05-27 Canadian Blood Services Method for treating thrombocytopenia with monoclonal ivig
US7473680B2 (en) 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
US7427469B2 (en) * 2002-11-05 2008-09-23 Institut Pasteur Method of treating cytomegalovirus with DC-SIGN blockers
AU2003303394B2 (en) 2002-12-23 2009-02-19 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
US20070048740A1 (en) * 2003-02-14 2007-03-01 Research Association For Biotechnology Full-length cDNA
AU2004229376B2 (en) * 2003-04-09 2007-12-13 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor
EP1670821A4 (en) * 2003-10-09 2006-11-29 Daewoong Co Ltd PROCESS FOR THE PURIFICATION OF HUMAN THROMBOPOIETIN WITH A HIGH SIALIC ACID CONTENT
ME02332B (me) * 2003-11-05 2016-06-30 Roche Glycart Ag Molekuli koji se vezuju za antigen sa povećanim afinitetom vezivanja za Fc receptor i efektornom funkcijom
EP2241331A3 (en) * 2003-12-15 2011-03-09 Alexion Pharmaceuticals, Inc. Novel anti-DC-SIGN antibodies
DK1699821T3 (da) * 2003-12-31 2012-07-16 Merck Patent Gmbh Fc-ERYTHROPOIETIN-FUSIONSPROTEIN MED FORBEDREDE FARMAKOKINETIKKER
AU2006265676B2 (en) 2005-06-30 2013-01-24 Centocor, Inc. Methods and compositions with enhanced therapeutic activity
BRPI0614850A2 (pt) * 2005-08-19 2011-04-19 Centocor Inc preparações de anticorpos resistentes a proteólise
US8470318B2 (en) * 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US20080286819A1 (en) 2005-11-07 2008-11-20 Ravetch Jeffrey V Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof
US20080206246A1 (en) * 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
EP3456351A1 (en) * 2006-04-05 2019-03-20 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
EP2091969A4 (en) 2006-10-27 2010-05-12 Univ Rockefeller POLYPEPTIDES WITH IMPROVED INFLAMMATORY INHIBITION AND REDUCED CYTOTOXIC PROPERTIES AND RELATED METHODS THEREFOR
US8114633B2 (en) 2007-12-27 2012-02-14 Baxter International Inc. Methods for differentiating plasma-derived protein from recombinant protein in a sample

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470318B2 (en) 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US10167332B2 (en) 2006-04-05 2019-01-01 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US10894832B2 (en) 2011-12-19 2021-01-19 The Rockefeller University Anti-inflammatory polypeptides
US11608379B2 (en) 2011-12-19 2023-03-21 The Rockefeller University Anti-inflammatory polypeptides
US11613579B2 (en) 2011-12-19 2023-03-28 The Rockefeller University Anti-inflammatory polypeptides
US10844125B2 (en) 2015-03-04 2020-11-24 The Rockefeller University Anti-inflammatory polypeptides

Also Published As

Publication number Publication date
JP6989979B2 (ja) 2022-02-15
US20210101961A1 (en) 2021-04-08
EP2010566B2 (en) 2017-07-26
JP7357382B2 (ja) 2023-10-06
CA2647524C (en) 2019-11-26
EP3456351A1 (en) 2019-03-20
EA022780B1 (ru) 2016-03-31
AU2007235413A1 (en) 2007-10-18
HK1124074A1 (en) 2009-07-03
ZA200808900B (en) 2009-10-28
US20170088608A1 (en) 2017-03-30
JP6084761B2 (ja) 2017-02-22
US20100278808A1 (en) 2010-11-04
IL194526A0 (en) 2011-08-01
WO2007117505A3 (en) 2008-10-16
US20130273040A1 (en) 2013-10-17
WO2007117505A2 (en) 2007-10-18
JP2017002041A (ja) 2017-01-05
US20190127446A1 (en) 2019-05-02
US10167332B2 (en) 2019-01-01
JP2018118985A (ja) 2018-08-02
MX2008012843A (es) 2009-01-19
US20190031738A1 (en) 2019-01-31
US20140323696A1 (en) 2014-10-30
EP2815768A2 (en) 2014-12-24
CN101432301B (zh) 2014-01-08
US20230121427A1 (en) 2023-04-20
AU2007235413B2 (en) 2012-08-02
EP2815768A3 (en) 2015-01-14
US20160176950A1 (en) 2016-06-23
JP2020117521A (ja) 2020-08-06
JP6686058B2 (ja) 2020-04-22
US20200385443A1 (en) 2020-12-10
US20170320935A1 (en) 2017-11-09
NZ572379A (en) 2012-06-29
CN101432301A (zh) 2009-05-13
JP6322849B2 (ja) 2018-05-16
EP2010566A2 (en) 2009-01-07
JP2015038086A (ja) 2015-02-26
CA2647524A1 (en) 2007-10-18
JP2009532477A (ja) 2009-09-10
EP2010566A4 (en) 2010-05-05
EP2010566B1 (en) 2014-09-03
JP2022031807A (ja) 2022-02-22
US20170218050A1 (en) 2017-08-03
IL194526A (en) 2012-04-30
US20190031737A1 (en) 2019-01-31
US20170283492A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
EA200870411A1 (ru) Полипептиды с усиленным противовоспалительным и пониженным цитотоксическим свойствами и связанные с ними способы
EA201070739A1 (ru) Полипептиды с усиленными противовоспалительными и сниженными цитотоксическими свойствами и связанные с ними способы
AU2018260863A1 (en) Human IgG1 Fc region variants and uses thereof
EA200970416A1 (ru) Полипептиды с усиленными противовоспалительными и сниженными цитотоксическими свойствами и способы, относящиеся к ним
RS54046B1 (en) ANTI-MIOSTATIN ANTITELA
NL301089I2 (nl) imlifidase
IL267186A (en) Epitopes of regulated T cells, preparations and uses
ES2694564T3 (es) Polipéptidos de interleucina-2 mutantes
MY157173A (en) Modified humanised anti-interleukin-18
EA200702008A1 (ru) Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека
BRPI0510674A (pt) variantes fc otimizadas
NZ588457A (en) Humanized anti-factor d antibodies and uses thereof
MX2013014961A (es) Variantes anticuerpos y usos de las mismas.
TW200732350A (en) Methods for generating monovalent IgG
PA8645301A1 (es) Anticuerpo anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina
ATE512988T1 (de) Antikörper gegen epcam und anwendungen davon
WO2006094192A3 (en) Humanized l243 antibodies
PE20120427A1 (es) Anticuerpos contra el receptor de cgrp humano
GB2450056A (en) CD47 Related compositions and methods for treating immunological diseases and disorders
NZ597023A (en) Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same
ITMI20031127A1 (it) Anticorpi anti-hgf-r e loro uso
MX2009008608A (es) Anticuerpos monoclonales anti-cxcl13.
ATE497392T1 (de) Therapie mit anti-cd4-antikörpern und bestrahlung
CL2008000493A1 (es) Polipeptido que se une especificamente a un dominio pdz de la proteina htra1; polinucleotido que lo codifica; metodo de produccion; anticuerpo que se une a el; y su uso para tratar patologias relacionadas con la proteina htra1.
ATE484749T1 (de) Von anti-trichinella-antikörpern erkannte polypeptide und ihre verwendung